CD Genomics is a premier global provider of high-quality Next-Generation Sequencing (NGS), high-throughput microarray, and advanced bioinformatics services, supporting cutting-edge research in oncology, neurology, and other areas of life science. Backed by a continuously upgraded technology platform, we integrate advanced NGS and microarray instrumentation to address increasingly complex research challenges in cancer biology, tumor heterogeneity, neurobiology, and disease mechanism studies.

With extensive expertise in data analysis, our senior bioinformaticians have processed tens of thousands of complex trace files across multiple sequencing systems, including Illumina HiSeq 4000, Illumina HiSeq X Ten, Illumina MiSeq, PacBio Sequel, and ABI 3730/3730XL analyzers, as well as next-generation additions such as the Illumina NovaSeq X Plus, PacBio Revio, and Oxford Nanopore PromethION.

In addition to standard sequencing services, CD Genomics provides advanced solutions in single-cell and spatial omics, epigenomics, long-read sequencing, and multi-omics integration. Our services are designed to support research involving tumor microenvironment analysis, cancer genomics, neurodegeneration research, and transcriptomic or epigenomic profiling. We are dedicated to serving pharmaceutical and biotech companies, academic institutions, and government agencies with reliable, research-focused genomic solutions.

Learn more about our full range of solutions at: https://www.cd-genomics.com/

https://rna.cd-genomics.com/